Treatment of Addiction to Nicotine in Schizophrenia

描述(由申请人提供)： 超过75%的精神分裂症患者依赖尼古丁，他们中的大多数人死于与吸烟有关的疾病。很少有人在初级保健或心理健康环境中获得尼古丁依赖治疗。不幸的是，很少有临床治疗研究，仍然非常需要开发、测试和传播心理健康环境中尼古丁依赖治疗的行为疗法和药物管理方法。需要治疗手册、培训计划和临床研究。这样的疗法应该反映这一人群的独特需求，并“适用于现实世界”。这项重新拨款申请回应了初步审查委员会的关注和有用的建议，并建议进一步开发和试行我们治疗精神分裂症尼古丁成瘾(TANS)的行为疗法方法。作为对审查委员会的答复，这一重新适用澄清并更好地将制革与其经验基础联系起来，涉及“现实世界的适用性”，改变了控制处理，并修改了评估单元。我们建议开发和测试TANS的第一阶段治疗开发产品(治疗手册、依从性量表和培训计划)，以及我们新的尼古丁依赖药物管理对照治疗(药物管理)。我们同意审查委员会的建议，在以下方面将TANS与较低强度的控制治疗进行比较：(1)最初三个月的参与、保留和长期戒除，(2)在四到六个月期间预防复发，(3)在以后的后续行动中长期戒除。在最初对20名受试者进行开放试验以开发治疗产品后，我们建议对100名受试者进行一项更大规模的研究，随机分为TANS和药物管理两组。这项拟议的研究很重要，因为它将创造两种现实世界适用的心理社会治疗，可以帮助精神卫生系统的临床医生更好地解决烟草问题，以及进行药物治疗或第二阶段治疗研究的研究人员。这项研究将评估这一人群的药物管理是否足够，以及延长治疗时间是否会改善长期结果。

DESCRIPTION (provided by applicant): Over 75% of patients with schizophrenia are nicotine dependent, and most of them die of smoking related illnesses. Few are offered nicotine dependence treatment in primary care or mental health settings. Unfortunately there have been few clinical treatment studies, and there continues to be a great need to develop, test, and disseminate behavioral therapy and medication management approaches for nicotine dependence treatment in mental health settings. Treatment manuals, training programs, and clinical studies are needed. Such therapies should reflect the unique needs of this population, and be "real world applicable." This grant reapplication responds to the concerns and helpful suggestions of the initial Review Committee and proposes to further develop and pilot test our behavioral therapy approach of Treating Addiction to Nicotine in Schizophrenia (TANS). In response to the Review Committee, this reapplication clarifies and better links TANS to its the empirical foundation, addresses "real world applicability," changes the control treatment, and modifies the assessment battery. We propose to develop and test Stage 1 Therapy Development Products (therapy manual, adherence scales, and training program) of TANS and our new control treatment of Nicotine Dependence Medication Management by Mental Health Providers (Medication Management). We agree with the Review Committee's suggestion to compare TANS to a lower intensity control treatment in regards to (1) engagement, retention, and extended abstinence during the initial three months, (2) relapse prevention during months four through six, and (3) longer-term abstinence at later follow-ups. After an initial open trial of 20 subjects to develop the therapy products, we propose to do a larger study of 100 subjects randomized to TANS versus Medication Management. The proposed study is important because it will create two real world applicable psychosocial treatments that could help clinicians in the mental health system better address tobacco and researchers doing medication or Stage II therapy studies. The study will assess whether medication management is sufficient in this population, and whether lengthening treatment will improve long-term outcomes.